Epizyme (EPZM) Tops Q4 EPS by 9c; Reacquires EZH2 Program Rights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Epizyme Announces 2014 Financial Results and Provides Corporate Update
March 12, 2015 7:01 AM EDTReacquired global rights to EPZ-6438 from Eisai, gaining full control of development, manufacturing and commercialization outside of Japan Data from ongoing Phase 1 dose escalation study of EPZ-6438 in B-cell non-Hodgkin lymphoma (NHL) and advanced solid tumors presented at EORTC-NCI-AACR Symposium; as of October 20, 2014 data cut-off: Three of five evaluable diffuse large B-cell lymphoma (DLBCL) patients achieved a partial response or better, including one patient with a complete response One of four evaluable follicular lymphoma patients achieved a partial response One of... More
Epizyme Reacquires Global Rights from Eisai for First-in-Class EZH2 Inhibitor EPZ-6438
March 12, 2015 7:00 AM EDTEpizyme obtains global operational responsibility and exclusive worldwide commercial rights outside of Japan
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that it has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Co. Ltd, or Eisai. Under the terms... More
